Unknown

Dataset Information

0

4-Amino-7-chloroquinolines: probing ligand efficiency provides botulinum neurotoxin serotype A light chain inhibitors with significant antiprotozoal activity.


ABSTRACT: Structurally simplified analogues of dual antimalarial and botulinum neurotoxin serotype A light chain (BoNT/A LC) inhibitor bis-aminoquinoline (1) were prepared. New compounds were designed to improve ligand efficiency while maintaining or exceeding the inhibitory potency of 1. Three of the new compounds are more active than 1 against both indications. Metabolically, the new inhibitors are relatively stable and nontoxic. 12, 14, and 15 are more potent BoNT/A LC inhibitors than 1. Additionally, 15 has excellent in vitro antimalarial efficacy, with IC90 values ranging from 4.45 to 12.11 nM against five Plasmodium falciparum (P.f.) strains: W2, D6, C235, C2A, and C2B. The results indicate that the same level of inhibitory efficacy provided by 1 can be retained/exceeded with less structural complexity. 12, 14, and 15 provide new platforms for the development of more potent dual BoNT/A LC and P.f. inhibitors adhering to generally accepted chemical properties associated with the druggability of synthetic molecules.

SUBMITTER: Opsenica IM 

PROVIDER: S-EPMC3880596 | biostudies-literature | 2013 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

4-Amino-7-chloroquinolines: probing ligand efficiency provides botulinum neurotoxin serotype A light chain inhibitors with significant antiprotozoal activity.

Opsenica Igor M IM   Tot Mikloš M   Gomba Laura L   Nuss Jonathan E JE   Sciotti Richard J RJ   Bavari Sina S   Burnett James C JC   Solaja Bogdan A BA  

Journal of medicinal chemistry 20130712 14


Structurally simplified analogues of dual antimalarial and botulinum neurotoxin serotype A light chain (BoNT/A LC) inhibitor bis-aminoquinoline (1) were prepared. New compounds were designed to improve ligand efficiency while maintaining or exceeding the inhibitory potency of 1. Three of the new compounds are more active than 1 against both indications. Metabolically, the new inhibitors are relatively stable and nontoxic. 12, 14, and 15 are more potent BoNT/A LC inhibitors than 1. Additionally,  ...[more]

Similar Datasets

| S-EPMC2529174 | biostudies-literature
| S-EPMC2854131 | biostudies-literature
| S-EPMC2583140 | biostudies-literature
| S-EPMC2394882 | biostudies-literature
| S-EPMC3230330 | biostudies-literature
| S-EPMC6118135 | biostudies-literature
| S-EPMC10681988 | biostudies-literature
| S-EPMC8539409 | biostudies-literature
| S-EPMC7291131 | biostudies-literature
| S-EPMC4025784 | biostudies-literature